Nature Medicine, Published online: 01 October 2024; doi:10.1038/s41591-024-03269-z
In the phase 3 EVER-132-002 trial, patients with HR+HER2− metastatic breast cancer from Asia were treated with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan or chemotherapy, and those receiving sacituzumab govitecan experienced prolonged progression-free survival compared with patients treated with chemotherapy.
Comments
No Trackbacks.